Next Article in Journal
Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles
Next Article in Special Issue
Dendritic Glycerol-Cholesterol Amphiphiles as Drug Delivery Systems: A Comparison between Monomeric and Polymeric Structures
Previous Article in Journal
The Impact of Inflammation on the In Vivo Activity of the Renal Transporters OAT1/3 in Pregnant Women Diagnosed with Acute Pyelonephritis
Previous Article in Special Issue
Dendritic Structures Functionalized with Boron Clusters, in Particular Carboranes, and Their Biological Properties
 
 
Article
Peer-Review Record

Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration

Pharmaceutics 2023, 15(10), 2428; https://doi.org/10.3390/pharmaceutics15102428
by Tony Wu, Chang Liu and Rangaramanujam M. Kannan *
Reviewer 1: Anonymous
Reviewer 2:
Reviewer 3:
Pharmaceutics 2023, 15(10), 2428; https://doi.org/10.3390/pharmaceutics15102428
Submission received: 21 August 2023 / Revised: 25 September 2023 / Accepted: 27 September 2023 / Published: 5 October 2023

Round 1

Reviewer 1 Report

In this manuscript, the authors presented a novel dendrimer-integrin binding peptide (D-ALG) which can treat AMD through systemic administration. Compared with free ALG-1001, D-ALG has better anti-degradation ability and can maintain higher local drug concentration, which greatly improves drug bioavailability. I recommend this manuscript to be accepted after addressing the following issues.

1. In wound healing assays, high doses of D-ALG work better, but low doses of ALG-1001 work better. Why are the results different for ALG-1001 and D-ALG?

2. In Western blot on endothelial cell activation, it is mentioned that "Compared to untreated, VEGF stimulated controls, the trend suggests that cells treated with D-ALG and ALG-1001 expressed lower levels of total FAK and phosphor-FAK." However, as shown in Figure 4, compared with the control group, ALG-1001 at high doses of 1mM did not significantly reduce FAK levels, and p-FAK levels were higher.

3. Does D-ALG have an effect on the activity of normal cells in the eye compared to ALG-1001, and how is the cytotoxicity of D-ALG?

 

4. In Figures S1-S6, it is recommended to label the molecular structure next to the peaks instead of lines. This will make the results more intuitive and convenient.

Author Response

Please see the attachment. Thanks!

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors report on dendrimer conjugation to improve delivery of integrin inhibitors for the treatment of neovascularization in retina. They conclude that this process decreases the enzymatic degradation and increases the stability of the compound. There seems to be a dose-escalation effect on vascular disruption in vitro and a healing and anti-inflammatory effects. The experimental methodology is solid and well-described. As this approach for retinovascular disease has been already tried in Phase 1 clinical studies it is a promising approach and any additional lab studies are contributory.

 

Comments:

Were there any cell/tissue toxicity studies done or previously reported?

Perhaps more anti-inflammatory cytokines could have been used to assess anti-inflammatory effect. Inhibition of IL1-beta and TNF-alpha may not give a full picture of anti-inflammatory effects.

Please standardize font in the Statistics section.

Author Response

Please see the attachment. Thanks!

Author Response File: Author Response.pdf

Reviewer 3 Report

A novel dendrimer modified integrin binding peptide was synthesized and showed good in vitro and in vivo anti-angiogenic activities. There is no revision comment in the present form. 

Author Response

No revisions. Thanks!

Round 2

Reviewer 1 Report

The authors have addressed all my concerns.

Back to TopTop